ReviewThe Journal of investigative dermatology2012
Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis.
Review in The Journal of investigative dermatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03859518 (Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.
- Association of multiple sclerosis with vitiligo: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Methodological strategies for mappingWorld journal of methodology · 2026Review
- Tinosporide promotes melanogenesis via activation of cAMP/PKA/CREB-MITF signaling in B16F10 and SK-MEL-2 cells.Journal of natural medicines · 2026Article
- Molecular Pathogenesis of Vitiligo: Emerging Roles of Epigenetic Regulation.Biomolecules & therapeutics · 2026Review
- Clinical Importance of Autoantibodies to SOX10 and Lamin A/C as Potential Biomarkers in Sera From Vitiligo Patients.Annals of dermatology · 2026Article
- Emerging Therapeutic Strategies for Nrf2-Associated Skin Disorders: From Photoaging to Autoimmunity.Antioxidants (Basel, Switzerland) · 2026Review
- Can the simple chicken MHC provide insight into the balance of autoimmunity and infectious disease?Immunogenetics · 2025Review
- Mutation-aware formulation: a genomic framework for equitable global dermocosmetics.Human genetics · 2025Article
- Current Concepts of Vitiligo Immunopathogenesis.Biomedicines · 2022Review
- The Current Status of Antioxidants in the Treatment of Vitiligo in China.Oxidative medicine and cellular longevity · 2022Article
- TLR4 gene polymorphisms in Egyptian vitiligo patients: insights into emerging association with clinical activity, family history, and response to therapy.Journal, genetic engineering & biotechnology · 2021Article
- Vulvar Lichen Sclerosus from Pathophysiology to Therapeutic Approaches: Evidence and Prospects.Biomedicines · 2021Review
- Can monocyte to HDL cholesterol ratio and monocyte to lymphocyte ratio be markers for inflammation and oxidative stress in patients with vitiligo? A preliminary study.Archives of dermatological research · 2021Observational
- Mechanisms of melanocyte death in vitiligo.Medicinal research reviews · 2021Review
- Article
- Association of GZMB polymorphisms and susceptibility to non-segmental vitiligo in a Korean population.Scientific reports · 2021Article
- Identification of key genes and pathways involved in vitiligo development based on integrated analysis.Medicine · 2020Article
- Validation of Susceptibility Loci for Vitiligo Identified by GWAS in the Chinese Han Population.Frontiers in genetics · 2020Article
- Skin-resident memory T cells as a potential new therapeutic target in vitiligo and melanoma.Pigment cell & melanoma research · 2019Review
- The convergence theory for vitiligo: A reappraisal.Experimental dermatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Generalized vitiligo (GV) is a complex disease in which patchy depigmentation results from autoimmune loss of melanocytes from affected regions. Genetic analyses of GV span six decades, with the goal of understanding biological mechanisms and elucidating pathways that underlie the disease. The earliest studies attempted to describe the mode of inheritance and genetic epidemiology. Early genetic association studies of biological candidate genes resulted in some successes, principally HLA and PTPN22, but in hindsight many such reports now seem to be false-positives. Later, genome-wide linkage studies of multiplex GV families identified NLRP1 and XBP1, which appear to be valid GV susceptibility genes that control key aspects of immune regulation. Recently, the application of genome-wide association studies to analysis of GV has produced a rich yield of validated GV susceptibility genes that encode components of biological pathways reaching from immune cells to the melanocyte. These genes and pathways provide insights into underlying pathogenetic mechanisms and possible triggers of GV, establish relationships to other autoimmune diseases, and may provide clues to potential new approaches to GV treatment and perhaps even prevention. These results thus validate the hopes and efforts of the early investigators who first attempted to comprehend the genetic basis of vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.